Full Press Release Details
JANUARY 2017 CORPORATE PRESENTATION HANDOUT
GERN
JANUARY 2017
Key Takeaway: JANUARY 2017 CORPORATE PRESENTATION HANDOUT
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+48%
120-day peak, hindsight
Typical move
4.4%
average across 4 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
Imetelstat
Phase 3 · Myelofibrosis